|
Sen. Julie A. Morrison
Filed: 3/21/2023
| | 10300SB1568sam002 | | LRB103 28639 BMS 59448 a |
|
|
1 | | AMENDMENT TO SENATE BILL 1568
|
2 | | AMENDMENT NO. ______. Amend Senate Bill 1568, AS AMENDED, |
3 | | by replacing everything after the enacting clause with the |
4 | | following:
|
5 | | "Section 5. The Illinois Insurance Code is amended by |
6 | | changing Section 370c.1 as follows: |
7 | | (215 ILCS 5/370c.1) |
8 | | Sec. 370c.1. Mental, emotional, nervous, or substance use |
9 | | disorder or condition parity. |
10 | | (a) On and after July 23, 2021 (the effective date of |
11 | | Public Act 102-135), every insurer that amends, delivers, |
12 | | issues, or renews a group or individual policy of accident and |
13 | | health insurance or a qualified health plan offered through |
14 | | the Health Insurance Marketplace in this State providing |
15 | | coverage for hospital or medical treatment and for the |
16 | | treatment of mental, emotional, nervous, or substance use |
|
| | 10300SB1568sam002 | - 2 - | LRB103 28639 BMS 59448 a |
|
|
1 | | disorders or conditions shall ensure prior to policy issuance |
2 | | that: |
3 | | (1) the financial requirements applicable to such |
4 | | mental, emotional, nervous, or substance use disorder or |
5 | | condition benefits are no more restrictive than the |
6 | | predominant financial requirements applied to |
7 | | substantially all hospital and medical benefits covered by |
8 | | the policy and that there are no separate cost-sharing |
9 | | requirements that are applicable only with respect to |
10 | | mental, emotional, nervous, or substance use disorder or |
11 | | condition benefits; and |
12 | | (2) the treatment limitations applicable to such |
13 | | mental, emotional, nervous, or substance use disorder or |
14 | | condition benefits are no more restrictive than the |
15 | | predominant treatment limitations applied to substantially |
16 | | all hospital and medical benefits covered by the policy |
17 | | and that there are no separate treatment limitations that |
18 | | are applicable only with respect to mental, emotional, |
19 | | nervous, or substance use disorder or condition benefits. |
20 | | (b) The following provisions shall apply concerning |
21 | | aggregate lifetime limits: |
22 | | (1) In the case of a group or individual policy of |
23 | | accident and health insurance or a qualified health plan |
24 | | offered through the Health Insurance Marketplace amended, |
25 | | delivered, issued, or renewed in this State on or after |
26 | | September 9, 2015 (the effective date of Public Act |
|
| | 10300SB1568sam002 | - 3 - | LRB103 28639 BMS 59448 a |
|
|
1 | | 99-480) that provides coverage for hospital or medical |
2 | | treatment and for the treatment of mental, emotional, |
3 | | nervous, or substance use disorders or conditions the |
4 | | following provisions shall apply: |
5 | | (A) if the policy does not include an aggregate |
6 | | lifetime limit on substantially all hospital and |
7 | | medical benefits, then the policy may not impose any |
8 | | aggregate lifetime limit on mental, emotional, |
9 | | nervous, or substance use disorder or condition |
10 | | benefits; or |
11 | | (B) if the policy includes an aggregate lifetime |
12 | | limit on substantially all hospital and medical |
13 | | benefits (in this subsection referred to as the |
14 | | "applicable lifetime limit"), then the policy shall |
15 | | either: |
16 | | (i) apply the applicable lifetime limit both |
17 | | to the hospital and medical benefits to which it |
18 | | otherwise would apply and to mental, emotional, |
19 | | nervous, or substance use disorder or condition |
20 | | benefits and not distinguish in the application of |
21 | | the limit between the hospital and medical |
22 | | benefits and mental, emotional, nervous, or |
23 | | substance use disorder or condition benefits; or |
24 | | (ii) not include any aggregate lifetime limit |
25 | | on mental, emotional, nervous, or substance use |
26 | | disorder or condition benefits that is less than |
|
| | 10300SB1568sam002 | - 4 - | LRB103 28639 BMS 59448 a |
|
|
1 | | the applicable lifetime limit. |
2 | | (2) In the case of a policy that is not described in |
3 | | paragraph (1) of subsection (b) of this Section and that |
4 | | includes no or different aggregate lifetime limits on |
5 | | different categories of hospital and medical benefits, the |
6 | | Director shall establish rules under which subparagraph |
7 | | (B) of paragraph (1) of subsection (b) of this Section is |
8 | | applied to such policy with respect to mental, emotional, |
9 | | nervous, or substance use disorder or condition benefits |
10 | | by substituting for the applicable lifetime limit an |
11 | | average aggregate lifetime limit that is computed taking |
12 | | into account the weighted average of the aggregate |
13 | | lifetime limits applicable to such categories. |
14 | | (c) The following provisions shall apply concerning annual |
15 | | limits: |
16 | | (1) In the case of a group or individual policy of |
17 | | accident and health insurance or a qualified health plan |
18 | | offered through the Health Insurance Marketplace amended, |
19 | | delivered, issued, or renewed in this State on or after |
20 | | September 9, 2015 (the effective date of Public Act |
21 | | 99-480) that provides coverage for hospital or medical |
22 | | treatment and for the treatment of mental, emotional, |
23 | | nervous, or substance use disorders or conditions the |
24 | | following provisions shall apply: |
25 | | (A) if the policy does not include an annual limit |
26 | | on substantially all hospital and medical benefits, |
|
| | 10300SB1568sam002 | - 5 - | LRB103 28639 BMS 59448 a |
|
|
1 | | then the policy may not impose any annual limits on |
2 | | mental, emotional, nervous, or substance use disorder |
3 | | or condition benefits; or |
4 | | (B) if the policy includes an annual limit on |
5 | | substantially all hospital and medical benefits (in |
6 | | this subsection referred to as the "applicable annual |
7 | | limit"), then the policy shall either: |
8 | | (i) apply the applicable annual limit both to |
9 | | the hospital and medical benefits to which it |
10 | | otherwise would apply and to mental, emotional, |
11 | | nervous, or substance use disorder or condition |
12 | | benefits and not distinguish in the application of |
13 | | the limit between the hospital and medical |
14 | | benefits and mental, emotional, nervous, or |
15 | | substance use disorder or condition benefits; or |
16 | | (ii) not include any annual limit on mental, |
17 | | emotional, nervous, or substance use disorder or |
18 | | condition benefits that is less than the |
19 | | applicable annual limit. |
20 | | (2) In the case of a policy that is not described in |
21 | | paragraph (1) of subsection (c) of this Section and that |
22 | | includes no or different annual limits on different |
23 | | categories of hospital and medical benefits, the Director |
24 | | shall establish rules under which subparagraph (B) of |
25 | | paragraph (1) of subsection (c) of this Section is applied |
26 | | to such policy with respect to mental, emotional, nervous, |
|
| | 10300SB1568sam002 | - 6 - | LRB103 28639 BMS 59448 a |
|
|
1 | | or substance use disorder or condition benefits by |
2 | | substituting for the applicable annual limit an average |
3 | | annual limit that is computed taking into account the |
4 | | weighted average of the annual limits applicable to such |
5 | | categories. |
6 | | (d) With respect to mental, emotional, nervous, or |
7 | | substance use disorders or conditions, an insurer shall use |
8 | | policies and procedures for the election and placement of |
9 | | mental, emotional, nervous, or substance use disorder or |
10 | | condition treatment drugs on their formulary that are no less |
11 | | favorable to the insured as those policies and procedures the |
12 | | insurer uses for the selection and placement of drugs for |
13 | | medical or surgical conditions and shall follow the expedited |
14 | | coverage determination requirements for substance abuse |
15 | | treatment drugs set forth in Section 45.2 of the Managed Care |
16 | | Reform and Patient Rights Act. |
17 | | (e) This Section shall be interpreted in a manner |
18 | | consistent with all applicable federal parity regulations |
19 | | including, but not limited to, the Paul Wellstone and Pete |
20 | | Domenici Mental Health Parity and Addiction Equity Act of |
21 | | 2008, final regulations issued under the Paul Wellstone and |
22 | | Pete Domenici Mental Health Parity and Addiction Equity Act of |
23 | | 2008 and final regulations applying the Paul Wellstone and |
24 | | Pete Domenici Mental Health Parity and Addiction Equity Act of |
25 | | 2008 to Medicaid managed care organizations, the Children's |
26 | | Health Insurance Program, and alternative benefit plans. |
|
| | 10300SB1568sam002 | - 7 - | LRB103 28639 BMS 59448 a |
|
|
1 | | (f) The provisions of subsections (b) and (c) of this |
2 | | Section shall not be interpreted to allow the use of lifetime |
3 | | or annual limits otherwise prohibited by State or federal law. |
4 | | (g) As used in this Section: |
5 | | "Financial requirement" includes deductibles, copayments, |
6 | | coinsurance, and out-of-pocket maximums, but does not include |
7 | | an aggregate lifetime limit or an annual limit subject to |
8 | | subsections (b) and (c). |
9 | | "Mental, emotional, nervous, or substance use disorder or |
10 | | condition" means a condition or disorder that involves a |
11 | | mental health condition or substance use disorder that falls |
12 | | under any of the diagnostic categories listed in the mental |
13 | | and behavioral disorders chapter of the current edition of the |
14 | | International Classification of Disease or that is listed in |
15 | | the most recent version of the Diagnostic and Statistical |
16 | | Manual of Mental Disorders. |
17 | | "Treatment limitation" includes limits on benefits based |
18 | | on the frequency of treatment, number of visits, days of |
19 | | coverage, days in a waiting period, or other similar limits on |
20 | | the scope or duration of treatment. "Treatment limitation" |
21 | | includes both quantitative treatment limitations, which are |
22 | | expressed numerically (such as 50 outpatient visits per year), |
23 | | and nonquantitative treatment limitations, which otherwise |
24 | | limit the scope or duration of treatment. A permanent |
25 | | exclusion of all benefits for a particular condition or |
26 | | disorder shall not be considered a treatment limitation. |
|
| | 10300SB1568sam002 | - 8 - | LRB103 28639 BMS 59448 a |
|
|
1 | | "Nonquantitative treatment" means those limitations as |
2 | | described under federal regulations (26 CFR 54.9812-1). |
3 | | "Nonquantitative treatment limitations" include, but are not |
4 | | limited to, those limitations described under federal |
5 | | regulations 26 CFR 54.9812-1, 29 CFR 2590.712, and 45 CFR |
6 | | 146.136.
|
7 | | (h) The Department of Insurance shall implement the |
8 | | following education initiatives: |
9 | | (1) By January 1, 2016, the Department shall develop a |
10 | | plan for a Consumer Education Campaign on parity. The |
11 | | Consumer Education Campaign shall focus its efforts |
12 | | throughout the State and include trainings in the |
13 | | northern, southern, and central regions of the State, as |
14 | | defined by the Department, as well as each of the 5 managed |
15 | | care regions of the State as identified by the Department |
16 | | of Healthcare and Family Services. Under this Consumer |
17 | | Education Campaign, the Department shall: (1) by January |
18 | | 1, 2017, provide at least one live training in each region |
19 | | on parity for consumers and providers and one webinar |
20 | | training to be posted on the Department website and (2) |
21 | | establish a consumer hotline to assist consumers in |
22 | | navigating the parity process by March 1, 2017. By January |
23 | | 1, 2018 the Department shall issue a report to the General |
24 | | Assembly on the success of the Consumer Education |
25 | | Campaign, which shall indicate whether additional training |
26 | | is necessary or would be recommended. |
|
| | 10300SB1568sam002 | - 9 - | LRB103 28639 BMS 59448 a |
|
|
1 | | (2) The Department, in coordination with the |
2 | | Department of Human Services and the Department of |
3 | | Healthcare and Family Services, shall convene a working |
4 | | group of health care insurance carriers, mental health |
5 | | advocacy groups, substance abuse patient advocacy groups, |
6 | | and mental health physician groups for the purpose of |
7 | | discussing issues related to the treatment and coverage of |
8 | | mental, emotional, nervous, or substance use disorders or |
9 | | conditions and compliance with parity obligations under |
10 | | State and federal law. Compliance shall be measured, |
11 | | tracked, and shared during the meetings of the working |
12 | | group. The working group shall meet once before January 1, |
13 | | 2016 and shall meet semiannually thereafter. The |
14 | | Department shall issue an annual report to the General |
15 | | Assembly that includes a list of the health care insurance |
16 | | carriers, mental health advocacy groups, substance abuse |
17 | | patient advocacy groups, and mental health physician |
18 | | groups that participated in the working group meetings, |
19 | | details on the issues and topics covered, and any |
20 | | legislative recommendations developed by the working |
21 | | group. |
22 | | (3) Not later than January 1 of each year, the |
23 | | Department, in conjunction with the Department of |
24 | | Healthcare and Family Services, shall issue a joint report |
25 | | to the General Assembly and provide an educational |
26 | | presentation to the General Assembly. The report and |
|
| | 10300SB1568sam002 | - 10 - | LRB103 28639 BMS 59448 a |
|
|
1 | | presentation shall: |
2 | | (A) Cover the methodology the Departments use to |
3 | | check for compliance with the federal Paul Wellstone |
4 | | and Pete Domenici Mental Health Parity and Addiction |
5 | | Equity Act of 2008, 42 U.S.C. 18031(j), and any |
6 | | federal regulations or guidance relating to the |
7 | | compliance and oversight of the federal Paul Wellstone |
8 | | and Pete Domenici Mental Health Parity and Addiction |
9 | | Equity Act of 2008 and 42 U.S.C. 18031(j). |
10 | | (B) Cover the methodology the Departments use to |
11 | | check for compliance with this Section and Sections |
12 | | 356z.23 and 370c of this Code. |
13 | | (C) Identify market conduct examinations or, in |
14 | | the case of the Department of Healthcare and Family |
15 | | Services, audits conducted or completed during the |
16 | | preceding 12-month period regarding compliance with |
17 | | parity in mental, emotional, nervous, and substance |
18 | | use disorder or condition benefits under State and |
19 | | federal laws and summarize the results of such market |
20 | | conduct examinations and audits. This shall include: |
21 | | (i) the number of market conduct examinations |
22 | | and audits initiated and completed; |
23 | | (ii) the benefit classifications examined by |
24 | | each market conduct examination and audit; |
25 | | (iii) the subject matter of each market |
26 | | conduct examination and audit, including |
|
| | 10300SB1568sam002 | - 11 - | LRB103 28639 BMS 59448 a |
|
|
1 | | quantitative and nonquantitative treatment |
2 | | limitations; and |
3 | | (iv) a summary of the basis for the final |
4 | | decision rendered in each market conduct |
5 | | examination and audit. |
6 | | Individually identifiable information shall be |
7 | | excluded from the reports consistent with federal |
8 | | privacy protections. |
9 | | (D) Detail any educational or corrective actions |
10 | | the Departments have taken to ensure compliance with |
11 | | the federal Paul Wellstone and Pete Domenici Mental |
12 | | Health Parity and Addiction Equity Act of 2008, 42 |
13 | | U.S.C. 18031(j), this Section, and Sections 356z.23 |
14 | | and 370c of this Code. |
15 | | (E) The report must be written in non-technical, |
16 | | readily understandable language and shall be made |
17 | | available to the public by, among such other means as |
18 | | the Departments find appropriate, posting the report |
19 | | on the Departments' websites. |
20 | | (i) The Parity Advancement Fund is created as a special |
21 | | fund in the State treasury. Moneys from fines and penalties |
22 | | collected from insurers for violations of this Section shall |
23 | | be deposited into the Fund. Moneys deposited into the Fund for |
24 | | appropriation by the General Assembly to the Department shall |
25 | | be used for the purpose of providing financial support of the |
26 | | Consumer Education Campaign, parity compliance advocacy, and |
|
| | 10300SB1568sam002 | - 12 - | LRB103 28639 BMS 59448 a |
|
|
1 | | other initiatives that support parity implementation and |
2 | | enforcement on behalf of consumers. |
3 | | (j) The Department of Insurance and the Department of |
4 | | Healthcare and Family Services shall convene and provide |
5 | | technical support to a workgroup of 11 members that shall be |
6 | | comprised of 3 mental health parity experts recommended by an |
7 | | organization advocating on behalf of mental health parity |
8 | | appointed by the President of the Senate; 3 behavioral health |
9 | | providers recommended by an organization that represents |
10 | | behavioral health providers appointed by the Speaker of the |
11 | | House of Representatives; 2 representing Medicaid managed care |
12 | | organizations recommended by an organization that represents |
13 | | Medicaid managed care plans appointed by the Minority Leader |
14 | | of the House of Representatives; 2 representing commercial |
15 | | insurers recommended by an organization that represents |
16 | | insurers appointed by the Minority Leader of the Senate; and a |
17 | | representative of an organization that represents Medicaid |
18 | | managed care plans appointed by the Governor. |
19 | | The workgroup shall provide recommendations to the General |
20 | | Assembly on health plan data reporting requirements that |
21 | | separately break out data on mental, emotional, nervous, or |
22 | | substance use disorder or condition benefits and data on other |
23 | | medical benefits, including physical health and related health |
24 | | services no later than December 31, 2019. The recommendations |
25 | | to the General Assembly shall be filed with the Clerk of the |
26 | | House of Representatives and the Secretary of the Senate in |
|
| | 10300SB1568sam002 | - 13 - | LRB103 28639 BMS 59448 a |
|
|
1 | | electronic form only, in the manner that the Clerk and the |
2 | | Secretary shall direct. This workgroup shall take into account |
3 | | federal requirements and recommendations on mental health |
4 | | parity reporting for the Medicaid program. This workgroup |
5 | | shall also develop the format and provide any needed |
6 | | definitions for reporting requirements in subsection (k). The |
7 | | research and evaluation of the working group shall include, |
8 | | but not be limited to: |
9 | | (1) claims denials due to benefit limits, if |
10 | | applicable; |
11 | | (2) administrative denials for no prior authorization; |
12 | | (3) denials due to not meeting medical necessity; |
13 | | (4) denials that went to external review and whether |
14 | | they were upheld or overturned for medical necessity; |
15 | | (5) out-of-network claims; |
16 | | (6) emergency care claims; |
17 | | (7) network directory providers in the outpatient |
18 | | benefits classification who filed no claims in the last 6 |
19 | | months, if applicable; |
20 | | (8) the impact of existing and pertinent limitations |
21 | | and restrictions related to approved services, licensed |
22 | | providers, reimbursement levels, and reimbursement |
23 | | methodologies within the Division of Mental Health, the |
24 | | Division of Substance Use Prevention and Recovery |
25 | | programs, the Department of Healthcare and Family |
26 | | Services, and, to the extent possible, federal regulations |
|
| | 10300SB1568sam002 | - 14 - | LRB103 28639 BMS 59448 a |
|
|
1 | | and law; and |
2 | | (9) when reporting and publishing should begin. |
3 | | Representatives from the Department of Healthcare and |
4 | | Family Services, representatives from the Division of Mental |
5 | | Health, and representatives from the Division of Substance Use |
6 | | Prevention and Recovery shall provide technical advice to the |
7 | | workgroup. |
8 | | (j-5) The Department of Insurance shall collect the |
9 | | following information: |
10 | | (1) The number of employment disability insurance |
11 | | plans offered in this State, including, but not limited |
12 | | to: |
13 | | (A) individual short-term policies; |
14 | | (B) individual long-term policies; |
15 | | (C) group short-term policies; and |
16 | | (D) group long-term policies. |
17 | | (2) The number of policies referenced in paragraph (1) |
18 | | of this subsection that limit mental health and substance |
19 | | use disorder benefits. |
20 | | (3) The average defined benefit period for the |
21 | | policies referenced in paragraph (1) of this subsection, |
22 | | both for those policies that limit and those policies that |
23 | | have no limitation on mental health and substance use |
24 | | disorder benefits. |
25 | | (4) Whether the policies referenced in paragraph (1) |
26 | | of this subsection are purchased on a voluntary or |
|
| | 10300SB1568sam002 | - 15 - | LRB103 28639 BMS 59448 a |
|
|
1 | | non-voluntary basis. |
2 | | (5) The identities of the individuals, entities, or a |
3 | | combination of the 2, that assume the cost associated with |
4 | | covering the policies referenced in paragraph (1) of this |
5 | | subsection. |
6 | | (6) The average defined benefit period for plans that |
7 | | cover physical disability and mental health and substance |
8 | | abuse without limitation, including, but not limited to: |
9 | | (A) individual short-term policies; |
10 | | (B) individual long-term policies; |
11 | | (C) group short-term policies; and |
12 | | (D) group long-term policies. |
13 | | (7) The average premiums for disability income |
14 | | insurance issued in this State for: |
15 | | (A) individual short-term policies that limit |
16 | | mental health and substance use disorder benefits; |
17 | | (B) individual long-term policies that limit |
18 | | mental health and substance use disorder benefits; |
19 | | (C) group short-term policies that limit mental |
20 | | health and substance use disorder benefits; |
21 | | (D) group long-term policies that limit mental |
22 | | health and substance use disorder benefits; |
23 | | (E) individual short-term policies that include |
24 | | mental health and substance use disorder benefits |
25 | | without limitation; |
26 | | (F) individual long-term policies that include |
|
| | 10300SB1568sam002 | - 16 - | LRB103 28639 BMS 59448 a |
|
|
1 | | mental health and substance use disorder benefits |
2 | | without limitation; |
3 | | (G) group short-term policies that include mental |
4 | | health and substance use disorder benefits without |
5 | | limitation; and |
6 | | (H) group long-term policies that include mental |
7 | | health and substance use disorder benefits without |
8 | | limitation. |
9 | | The Department shall present its findings regarding |
10 | | information collected under this subsection (j-5) to the |
11 | | General Assembly no later than April 30, 2024. Information |
12 | | regarding a specific insurance provider's contributions to the |
13 | | Department's report shall be exempt from disclosure under |
14 | | paragraph (t) of subsection (1) of Section 7 of the Freedom of |
15 | | Information Act. The aggregated information gathered by the |
16 | | Department shall not be exempt from disclosure under paragraph |
17 | | (t) of subsection (1) of Section 7 of the Freedom of |
18 | | Information Act. |
19 | | (k) An insurer that amends, delivers, issues, or renews a |
20 | | group or individual policy of accident and health insurance or |
21 | | a qualified health plan offered through the health insurance |
22 | | marketplace in this State providing coverage for hospital or |
23 | | medical treatment and for the treatment of mental, emotional, |
24 | | nervous, or substance use disorders or conditions shall submit |
25 | | an annual report, the format and definitions for which will be |
26 | | developed by the workgroup in subsection (j), to the |
|
| | 10300SB1568sam002 | - 17 - | LRB103 28639 BMS 59448 a |
|
|
1 | | Department, or, with respect to medical assistance, the |
2 | | Department of Healthcare and Family Services starting on or |
3 | | before July 1, 2020 that contains the following information |
4 | | separately for inpatient in-network benefits, inpatient |
5 | | out-of-network benefits, outpatient in-network benefits, |
6 | | outpatient out-of-network benefits, emergency care benefits, |
7 | | and prescription drug benefits in the case of accident and |
8 | | health insurance or qualified health plans, or inpatient, |
9 | | outpatient, emergency care, and prescription drug benefits in |
10 | | the case of medical assistance: |
11 | | (1) A summary of the plan's pharmacy management |
12 | | processes for mental, emotional, nervous, or substance use |
13 | | disorder or condition benefits compared to those for other |
14 | | medical benefits. |
15 | | (2) A summary of the internal processes of review for |
16 | | experimental benefits and unproven technology for mental, |
17 | | emotional, nervous, or substance use disorder or condition |
18 | | benefits and those for
other medical benefits. |
19 | | (3) A summary of how the plan's policies and |
20 | | procedures for utilization management for mental, |
21 | | emotional, nervous, or substance use disorder or condition |
22 | | benefits compare to those for other medical benefits. |
23 | | (4) A description of the process used to develop or |
24 | | select the medical necessity criteria for mental, |
25 | | emotional, nervous, or substance use disorder or condition |
26 | | benefits and the process used to develop or select the |
|
| | 10300SB1568sam002 | - 18 - | LRB103 28639 BMS 59448 a |
|
|
1 | | medical necessity criteria for medical and surgical |
2 | | benefits. |
3 | | (5) Identification of all nonquantitative treatment |
4 | | limitations that are applied to both mental, emotional, |
5 | | nervous, or substance use disorder or condition benefits |
6 | | and medical and surgical benefits within each |
7 | | classification of benefits. |
8 | | (6) The results of an analysis that demonstrates that |
9 | | for the medical necessity criteria described in |
10 | | subparagraph (A) and for each nonquantitative treatment |
11 | | limitation identified in subparagraph (B), as written and |
12 | | in operation, the processes, strategies, evidentiary |
13 | | standards, or other factors used in applying the medical |
14 | | necessity criteria and each nonquantitative treatment |
15 | | limitation to mental, emotional, nervous, or substance use |
16 | | disorder or condition benefits within each classification |
17 | | of benefits are comparable to, and are applied no more |
18 | | stringently than, the processes, strategies, evidentiary |
19 | | standards, or other factors used in applying the medical |
20 | | necessity criteria and each nonquantitative treatment |
21 | | limitation to medical and surgical benefits within the |
22 | | corresponding classification of benefits; at a minimum, |
23 | | the results of the analysis shall: |
24 | | (A) identify the factors used to determine that a |
25 | | nonquantitative treatment limitation applies to a |
26 | | benefit, including factors that were considered but |
|
| | 10300SB1568sam002 | - 19 - | LRB103 28639 BMS 59448 a |
|
|
1 | | rejected; |
2 | | (B) identify and define the specific evidentiary |
3 | | standards used to define the factors and any other |
4 | | evidence relied upon in designing each nonquantitative |
5 | | treatment limitation; |
6 | | (C) provide the comparative analyses, including |
7 | | the results of the analyses, performed to determine |
8 | | that the processes and strategies used to design each |
9 | | nonquantitative treatment limitation, as written, for |
10 | | mental, emotional, nervous, or substance use disorder |
11 | | or condition benefits are comparable to, and are |
12 | | applied no more stringently than, the processes and |
13 | | strategies used to design each nonquantitative |
14 | | treatment limitation, as written, for medical and |
15 | | surgical benefits; |
16 | | (D) provide the comparative analyses, including |
17 | | the results of the analyses, performed to determine |
18 | | that the processes and strategies used to apply each |
19 | | nonquantitative treatment limitation, in operation, |
20 | | for mental, emotional, nervous, or substance use |
21 | | disorder or condition benefits are comparable to, and |
22 | | applied no more stringently than, the processes or |
23 | | strategies used to apply each nonquantitative |
24 | | treatment limitation, in operation, for medical and |
25 | | surgical benefits; and |
26 | | (E) disclose the specific findings and conclusions |
|
| | 10300SB1568sam002 | - 20 - | LRB103 28639 BMS 59448 a |
|
|
1 | | reached by the insurer that the results of the |
2 | | analyses described in subparagraphs (C) and (D) |
3 | | indicate that the insurer is in compliance with this |
4 | | Section and the Mental Health Parity and Addiction |
5 | | Equity Act of 2008 and its implementing regulations, |
6 | | which includes 42 CFR Parts 438, 440, and 457 and 45 |
7 | | CFR 146.136 and any other related federal regulations |
8 | | found in the Code of Federal Regulations. |
9 | | (7) Any other information necessary to clarify data |
10 | | provided in accordance with this Section requested by the |
11 | | Director, including information that may be proprietary or |
12 | | have commercial value, under the requirements of Section |
13 | | 30 of the Viatical Settlements Act of 2009. |
14 | | (l) An insurer that amends, delivers, issues, or renews a |
15 | | group or individual policy of accident and health insurance or |
16 | | a qualified health plan offered through the health insurance |
17 | | marketplace in this State providing coverage for hospital or |
18 | | medical treatment and for the treatment of mental, emotional, |
19 | | nervous, or substance use disorders or conditions on or after |
20 | | January 1, 2019 (the effective date of Public Act 100-1024) |
21 | | shall, in advance of the plan year, make available to the |
22 | | Department or, with respect to medical assistance, the |
23 | | Department of Healthcare and Family Services and to all plan |
24 | | participants and beneficiaries the information required in |
25 | | subparagraphs (C) through (E) of paragraph (6) of subsection |
26 | | (k). For plan participants and medical assistance |
|
| | 10300SB1568sam002 | - 21 - | LRB103 28639 BMS 59448 a |
|
|
1 | | beneficiaries, the information required in subparagraphs (C) |
2 | | through (E) of paragraph (6) of subsection (k) shall be made |
3 | | available on a publicly-available website whose web address is |
4 | | prominently displayed in plan and managed care organization |
5 | | informational and marketing materials. |
6 | | (m) In conjunction with its compliance examination program |
7 | | conducted in accordance with the Illinois State Auditing Act, |
8 | | the Auditor General shall undertake a review of
compliance by |
9 | | the Department and the Department of Healthcare and Family |
10 | | Services with Section 370c and this Section. Any
findings |
11 | | resulting from the review conducted under this Section shall |
12 | | be included in the applicable State agency's compliance |
13 | | examination report. Each compliance examination report shall |
14 | | be issued in accordance with Section 3-14 of the Illinois |
15 | | State
Auditing Act. A copy of each report shall also be |
16 | | delivered to
the head of the applicable State agency and |
17 | | posted on the Auditor General's website. |
18 | | (Source: P.A. 102-135, eff. 7-23-21; 102-579, eff. 8-25-21; |
19 | | 102-813, eff. 5-13-22.)".
|